Skip to content

Beijing Disability Risk and Ageing Monitoring Study

Beijing Disability Risk and Ageing Monitoring Study

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT06394817
Acronym
BEAM
Enrollment
2000
Registered
2024-05-01
Start date
2023-02-20
Completion date
2063-05-31
Last updated
2024-06-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Age Problem, Death, Disability

Keywords

Disability, Ageing, Cohort

Brief summary

This is a community-based prospective cohort study in Beijing, China. The study has been initialized in 2023 and enrolled older residents. This study aims to develop disability risk assessment standards and an early warning model for older adults.

Detailed description

This is a community-based prospective cohort study. Individuals who aged 60 years or older, lived in the communities for more than 1 year, and signed the informed consent form were enrolled in the present study. The study has been initialized in 2023 and aimed to develop an early warning model and a series of disability risk assessment methods for older adults. This work consists of three steps as following. First, we will build a community-based cohort and thus set up a database. Second, an intelligence model for disability risk assessment will be developed using the database. Third, a series of procedures will be established according to the risk assessment model.

Interventions

OTHERNo intervention

No intervention

Sponsors

Xuanwu Hospital, Beijing
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
60 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

* Aged 60 years or older * Lived in the community for more than 1 year * Signed the informed consent form

Exclusion criteria

* Cannot complete the survey

Design outcomes

Primary

MeasureTime frameDescription
The prevalence and incidence of functional disability using a population-based surveyAn average of 1 to 2 yearsFunctional disability was measured by Activities of Daily Living, cognitive function (Mini-Mental State Examination) and movement disorder(Short Physical Performance Battery) collected by questionnaires.The minimum value of the Activities of Daily Living is 0, and the maximum value is 100, the higher the score, the better the outcome.The minimum value of the Mini-Mental State Examination is 0, and the maximum value is 30, the higher the score, the better the outcome.The minimum value of the Short Physical Performance Battery is 0, and the maximum value is 12, the higher the score, the better the outcome.
The prevalence and incidence of mild cognitive impairment using a population-based surveyAn average of 1 to 2 yearsMild cognitive impairment was measured using Mini-Mental State Examination collected by questionnaire.The minimum value of the Mini-Mental State Examination is 0, and the maximum value is 30, the higher the score, the better the outcome.
The prevalence and incidence of dementia using a population-based surveyAn average of 1 to 2 yearsDementia was determined by diagnosis of hospitalization or diagnosis of death or Clinical Dementia Rating scale. The minimum value of the Clinical Dementia Rating is 0, and the maximum value is 3, the higher the score, the worse the outcome.
The conversion rate of normal to mild cognitive impairmentAn average of 1 to 2 yearsPercentage of enrolled population that convert from normal to mild cognitive impairment
The conversion rate of mild cognitive impairment to dementiaAn average of 1 to 2 yearsPercentage of enrolled population that convert from mild cognitive impairment to dementia
The genetic and environmental factors for mild cognitive impairment and dementia at genomic and expression levelsAn average of 1 to 2 yearsDiscover risk factors including genetic susceptibility loci (APOE genes and other risk genes) using gene sequencing, cardiovascular risk factors (blood glucose, cholesterol, homocysteine) using laboratory tests, and unhealthy lifestyle using questionnaire.
The biomarkers for normal, mild cognitive impairment, and dementia diagnosisAn average of 1 to 2 yearsHumoral biomarkers are included Aβ42, Aβ40, phosphated tau and total tau in plasma, cerebrospinal fluid, saliva, and urine. Imaging biomarkers are included cerebral volume, glucose metabolism, amyloid and tau deposition of whole brain or hippocampus.
The prevalence and incidence of movement disorder using a population-based surveyAn average of 1 to 2 yearsMovement disorder was measured using Short Physical Performance Battery collected by questionnaire.The minimum value of the Short Physical Performance Battery is 0, and the maximum value is 12, the higher the score, the better the outcome.

Countries

China

Contacts

Primary ContactYi Tang, MD., PhD
tangyi@xwhosp.org00861083199456

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026